In addition, the patients with the 25% highest TGF-β pathway activity scores exhibited a significantly shorter progression-free interval compared to the patients with the 25% lowest scores, indicative of a reduced benefit from endocrine therapy (SFig. 7A); the JAK pathway activity score was not associated with endocrine therapy resistance in luminal breast cancer patients (SFig. 7B). The gene discussed is TGFB1; the disease is breast cancer.